Intra-Cellular Stock Analysis

ITCI
 Stock
  

USD 55.17  1.91  3.35%   

Intra-Cellular Ther price drop over the last few months may raise some interest from stockholders. The stock closed today at a share price of 55.17 on 896,500 in trading volume. The company executives were not very successful in positioning the firm resources to exploit market volatility in June. However, diversifying your holdings with Intra-Cellular Ther or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.44. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Intra-Cellular Ther partners.
Please see Risk vs Return Analysis.
  
Refresh
The Intra-Cellular Ther stock analysis report makes it easy to digest most publicly released information about Intra-Cellular Ther and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Intra-Cellular Stock analysis module also helps to analyze the Intra-Cellular Ther price relationship with some important fundamental indicators such as market cap and management efficiency.

Intra-Cellular Stock Analysis Notes

About 87.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.2. Intra-Cellular Ther had not issued any dividends in recent years. Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people. To learn more about Intra-Cellular Ther call Sharon Mates at 646 440-9333 or check out www.intracellulartherapies.com.

Intra-Cellular Ther Quarterly Cost of Revenue

3.15 Million

Share

Intra-Cellular Ther Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Intra-Cellular Ther's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Intra-Cellular Ther or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Intra-Cellular Ther generated a negative expected return over the last 90 days
Intra-Cellular Ther has high historical volatility and very poor performance
Intra-Cellular Ther has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 83.8 M. Net Loss for the year was (284.13 M) with loss before overhead, payroll, taxes, and interest of (13.08 M).
Intra-Cellular Ther currently holds about 412.33 M in cash with (259.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41.
Intra-Cellular Ther has a frail financial position based on the latest SEC disclosures
Over 87.0% of the company shares are owned by institutional investors
Latest headline from citywireusa.com: Revealed 10 shares the worlds top investors are buying in the selloff - Citywire USA

Intra-Cellular Ther Upcoming and Recent Events

Earnings reports are used by Intra-Cellular Ther to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intra-Cellular Ther previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report9th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Intra-Cellular Largest EPS Surprises

Earnings surprises can significantly impact Intra-Cellular Ther's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2014-11-03
2014-09-30-0.28-0.220.0621 
2014-05-05
2014-03-31-0.23-0.170.0626 
2017-11-08
2017-09-30-0.6163-0.530.086314 
View All Earnings Estimates

Intra-Cellular Ther SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Intra-Cellular Ther prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Intra-Cellular Ther investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Intra-Cellular Ther specific information freely available to individual and institutional investors to make a timely investment decision.
13th of June 2022
Submission of Matters to a Vote of Security Holders
View
10th of May 2022
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
25th of April 2022
Financial Statements and Exhibits. Other Events
View
21st of April 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
1st of March 2022
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
10th of February 2022
Unclassified Corporate Event
View
9th of February 2022
Unclassified Corporate Event
View
3rd of February 2022
Unclassified Corporate Event
View

Intra-Cellular Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Intra-Cellular Ther is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Intra-Cellular Ther backward and forwards among themselves. Intra-Cellular Ther's institutional investor refers to the entity that pools money to purchase Intra-Cellular Ther's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares11 M670.3 M
Vanguard Group IncCommon Shares7.8 M476.6 M
Wasatch Advisors IncCommon Shares7.5 M457.6 M
Blackrock IncCommon Shares6.5 M395.9 M
Wellington Management Group LlpCommon Shares4.1 M248.5 M
Bellevue Group AgCommon Shares3.4 M209.9 M
Marshall Wace LlpCommon Shares2.5 M154.2 M
Note, although Intra-Cellular Ther's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Intra-Cellular Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 4.49 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Intra-Cellular Ther's market, we take the total number of its shares issued and multiply it by Intra-Cellular Ther's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Intra-Cellular Profitablity

Intra-Cellular Ther's profitability indicators refer to fundamental financial ratios that showcase Intra-Cellular Ther's ability to generate income relative to its revenue or operating costs. If, let's say, Intra-Cellular Ther is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Intra-Cellular Ther's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Intra-Cellular Ther's profitability requires more research than a typical breakdown of Intra-Cellular Ther's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(53.16) (57.36) 
Return on Average Assets(0.48) (0.52) 
Return on Average Equity(0.55) (0.59) 
Return on Invested Capital(0.63) (0.65) 
Return on Sales(3.39) (3.66) 

Management Efficiency

The entity has return on total asset (ROA) of (29.58) % which means that it has lost $29.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (52.87) %, meaning that it created substantial loss on money invested by shareholders. Intra-Cellular Ther management efficiency ratios could be used to measure how well intra-cellular ther manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -57.36. The current Return on Average Assets is estimated to decrease to -0.52. Intra-Cellular Ther Asset Turnover is most likely to slightly decrease in the upcoming years. The last year's value of Asset Turnover was reported at 0.14. The current Tangible Assets Book Value per Share is estimated to increase to 6.98, while Total Assets are projected to decrease to roughly 435.4 M.
Last ReportedProjected for 2022
Book Value per Share 5.14  6.05 
Enterprise Value over EBIT(15.00) (16.18) 
Enterprise Value over EBITDA(14.75) (15.92) 
Price to Book Value 10.20  8.15 
Tangible Assets Book Value per Share 6.03  6.98 
Enterprise Value4.2 B4.5 B
Tangible Asset Value489.9 M435.4 M

Technical Drivers

As of the 4th of July, Intra-Cellular Ther retains the risk adjusted performance of (0.023355), and Market Risk Adjusted Performance of (0.10). Intra-Cellular Ther technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down nineteen technical drivers for Intra-Cellular Ther, which can be compared to its competitors. Please check out Intra-Cellular Ther information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Intra-Cellular Ther is priced fairly, providing market reflects its last-minute price of 55.17 per share. Given that Intra-Cellular Ther has jensen alpha of 0.0752, we strongly advise you to confirm Intra-Cellular Ther's regular market performance to make sure the company can sustain itself at a future point.

Intra-Cellular Ther Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Double Exponential Moving Average indicator was developed by Patrick Mulloy. It consists of a single exponential moving average and a double exponential moving average. This indicator is more responsive to Intra-Cellular Ther changes than the simple moving average.
.

Intra-Cellular Ther Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intra-Cellular Ther insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intra-Cellular Ther's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intra-Cellular Ther insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Joel Marcus over a month ago via Macroaxis 
Exercise or conversion by Joel Marcus of 14189 shares of Intra-Cellular Ther subject to Rule 16b-3
Michael Halstead over a month ago via Macroaxis 
Exercise or conversion by Michael Halstead of 111 shares of Intra-Cellular Ther subject to Rule 16b-3
Salas Eduardo Rene over two months ago via Macroaxis 
Acquisition by Salas Eduardo Rene of 20000 shares of Intra-Cellular Ther subject to Rule 16b-3
Rory Riggs over two months ago via Macroaxis 
Sale by Rory Riggs of 20686 shares of Intra-Cellular Ther
Mark Neumann over two months ago via Macroaxis 
Exercise or conversion by Mark Neumann of 86348 shares of Intra-Cellular Ther subject to Rule 16b-3
Rory Riggs over three months ago via Macroaxis 
Sale by Rory Riggs of 15736 shares of Intra-Cellular Ther
Suresh Durgam over three months ago via Macroaxis 
Acquisition by Suresh Durgam of 22034 shares of Intra-Cellular Ther subject to Rule 16b-3
Sharon Mates over three months ago via Macroaxis 
Exercise or conversion by Sharon Mates of 38925 shares of Intra-Cellular Ther subject to Rule 16b-3
Suresh Durgam over three months ago via Macroaxis 
Sale by Suresh Durgam of 3860 shares of Intra-Cellular Ther
Suresh Durgam over three months ago via Macroaxis 
Exercise or conversion by Suresh Durgam of 7906 shares of Intra-Cellular Ther subject to Rule 16b-3
Suresh Durgam over three months ago via Macroaxis 
Sale by Suresh Durgam of 1203 shares of Intra-Cellular Ther
Suresh Durgam over three months ago via Macroaxis 
Sale by Suresh Durgam of 6223 shares of Intra-Cellular Ther

Intra-Cellular Ther Predictive Daily Indicators

Intra-Cellular Ther intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Intra-Cellular Ther stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Intra-Cellular Ther Forecast Models

Intra-Cellular Ther time-series forecasting models is one of many Intra-Cellular Ther's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Intra-Cellular Ther's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Intra-Cellular Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Intra-Cellular Ther stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Intra-Cellular shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Intra-Cellular Ther. By using and applying Intra-Cellular Stock analysis, traders can create a robust methodology for identifying Intra-Cellular entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 42.74  42.49 
EBITDA Margin(3.38) (3.65) 
Gross Margin 0.90  0.89 
Profit Margin(3.39) (3.66) 
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun for the treatment of Parkinsons disease and heart failure ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Current Intra-Cellular Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Intra-Cellular analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Intra-Cellular analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
60.0Buy7Odds
Intra-Cellular Ther current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Intra-Cellular analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Intra-Cellular stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Intra-Cellular Ther, talking to its executives and customers, or listening to Intra-Cellular conference calls.
Intra-Cellular Analyst Advice Details

Intra-Cellular Stock Analysis Indicators

Intra-Cellular Ther stock analysis indicators help investors evaluate how Intra-Cellular Ther stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Intra-Cellular Ther shares will generate the highest return on investment. By understating and applying Intra-Cellular Ther stock analysis, traders can identify Intra-Cellular Ther position entry and exit signals to maximize returns.
Quick Ratio8.11
Fifty Two Week Low28.40
Revenue Growth106.10%
Shares Short Prior Month3.85M
Average Daily Volume Last 10 Day942.74k
Average Daily Volume In Three Month866.99k
Shares Percent Shares Out3.54%
Gross Margins-15.60%
Short Percent Of Float4.07%
Forward Price Earnings-45.60
Float Shares86.54M
Fifty Two Week High66.00
Enterprise Value To Ebitda-15.25
Fifty Day Average55.00
Two Hundred Day Average49.40
Enterprise Value To Revenue51.91
Please see Risk vs Return Analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.